CTOs on the Move

MIE Labs

www.mielabs.com

 
MIE Labs will be your preferred partner for integrated electronics product development. We work in partnership with customers, vendors and associates to provide optimal solutions for the most technically challenging product developments. Services include analog/mixed-signal IC design and development, expert consulting and product development.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.mielabs.com
  • 9250 Bendix Road North Suite 725
    Columbia, MD USA 21045
  • Phone: 410.440.2860

Executives

Name Title Contact Details

Similar Companies

Advanced Knowledge Associates

Advanced Knowledge Associates is a Cupertino, CA-based company in the Computers and Electronics sector.

SiberCore Technologies

SiberCore Technologies is a Kanata, ON-based company in the Computers and Electronics sector.

Spectel Research Corp

Spectel Research Corp is a Palo Alto, CA-based company in the Computers and Electronics sector.

Newport Digital Technologies

Newport Digital Technologies, Inc (www.newportdt.com) is a technology solutions driven company organized to focus on serving four of the fastest-emerging businesses in the technology space - Digital Signage and LED Lighting, RFID (radio-frequency identification), and WiMax solutions.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.